Codexis Stock News

Codexis (NASDAQ:CDXS) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close.The consensus EPS Estimate is -$0.20 (-233.3% Y/Y) and the…

REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its fourth quarter and fiscal year 2021 financial results on Thursday, February 24, 2022, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Companys financial results and provide a business update.

Codexis (CDXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

REDWOOD CITY, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS ), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation (ODD) for CDX-6512 for the treatment of homocystinuria. CDX-6512 is a gastrointestinal-stable methionine-gamma-lyase, as a potential orally-administered enzyme therapy for homocystinuria (HCU). The FDA also granted the company rare pediatric disease (RPD) designation for CDX-6512. CDX-6512 is currently in pre-IND development and is the most advanced wholly owned program in the Company''s biotherapeutics pipeline. "The orphan drug and rare pediatric disease designations for CDX-6512 further build upon the momentum our engineered enzymes have generated as potential first-in-class oral therapeutics for inborn errors of metabolism," said John Nicols, President and CEO of Codexis. "These designations represent an important step forward in the development of CDX-6512 as a potential treatment of homocystinuria and we look forward to continuing its advancement toward the clinic." CDX-6512 is a gastrointestinal-stable enzyme specifically engineered to be highly resistant to both the acidic conditions of the stomach and to proteases of the upper intestines, enabling it to effectively degrade methionine that is liberated from protein digestion.

In this article we will take a look at whether hedge funds think Codexis, Inc. (NASDAQ:CDXS) is a good investment right now.

Codexis (CDXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

David V. Smith to join Board of Directors Elizabeth Smith and Richard Lopez, M.D., to join Scientific Advisory Board ALAMEDA, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Acepodia , a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care, today announced it has appointed David V. Smith to its Board of Directors and Elizabeth Smith and Richard Lopez, M.D., to its Scientific Advisory Board. "Following our recent Series C funding milestone, we are pleased to bring on a strong roster of industry leaders who bring deep expertise across allogeneic cell therapy development, regulatory affairs, and finance, to help us bring forth next-generation cell therapies for the people who need them most," said Sonny Hsiao, Ph.D., chief executive officer, president and co-founder of Acepodia. David V. Smith Mr. Smith currently serves as a member of the Board of Directors at Codexis and Neurelis and most recently served as Executive Vice President and Chief Financial Officer of Five Prime Therapeutics, acquired by Amgen in 2021.

Two sample Breakout Stocks for Week 52 with better than 10% short-term upside potential and a Dow stock pick. This past week, two stocks beat 10% peak gains in FLGT +19.1% and DYAI +13.8% with Momentu

Here we discuss three stocks - CDXS, PGEN, VERV - engaged in the field of scientific biology that investors may keep a tab of as these have the potential to generate wealth for them going forward.

Shares of Codexis, Inc. (NASDAQ:CDXS) saw an uptick in trading volume on Thursday . 51,678 shares traded hands during trading, a decline of 92% from the previous sessions volume of 687,631 shares.The stock last traded at $33.21 and had previously closed at $31.90. Several brokerages have recently commented on CDXS. Craig Hallum restated a buy []

Codexis, Inc. (NASDAQ:CDXS) Director Dennis P. Wolf sold 5,000 shares of the firms stock in a transaction on Monday, December 20th. The shares were sold at an average price of $28.83, for a total transaction of $144,150.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. NASDAQ CDXS []

REDWOOD CITY, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its Codex® HiTemp Reverse Transcriptase for use in one-step quantitative reverse transcription PCR (RT-qPCR). RT-qPCR is currently used widely for viral diagnostic tests, including SARS-CoV-2 nucleic acid amplification tests. This enzyme is specifically engineered and optimized for enhanced thermostability and robustness to address known challenges in handling clinical samples.

Key Prominent Players Covered in the Enzymes Market are BASF, Codexis Inc., Amano Enzyme Inc., DSM, Dupont De Nemours & Co., ABF PLC, AB Enzymes, Dyadic International Inc., Advanced Enzyme Technology Ltd., Affymetrix Inc., Bbi Enzymes Ltd., Basf, Codexis Inc., Nagase & Co. Ltd., Life Technologies, Roche Holding Ag., Sanofi S.A. Key Prominent Players Covered in the Enzymes Market are BASF, Codexis Inc., Amano Enzyme Inc., DSM, Dupont De Nemours & Co., ABF PLC, AB Enzymes, Dyadic International Inc., Advanced Enzyme Technology Ltd., Affymetrix Inc., Bbi Enzymes Ltd., Basf, Codexis Inc., Nagase & Co. Ltd., Life Technologies, Roche Holding Ag., Sanofi S.A.

Wall Street brokerages forecast that Codexis, Inc. (NASDAQ:CDXS) will report earnings per share (EPS) of ($0.18) for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Codexis earnings, with the lowest EPS estimate coming in at ($0.25) and the highest estimate coming in at ($0.07). Codexis reported earnings of ($0.06) per []

In the last trading session, 1.07 million Codexis Inc. (NASDAQ:CDXS) shares changed hands as the company’s beta touched 1.60. With the company’s per share price at $33.91 changed hands at $2.47 or 7.86% during last session, the market valuation stood at $2.32B. CDXS’s last price was a discount, traded about -23.89% off its 52-week high … Codexis Inc. (NASDAQ: CDXS): The Stock To Invest In Over The Next Few Months Read More »